Resapp share (ASX:RAP) price climbs 5% on Chinese patent news

Investors are piling into Resapp on huge volume today.

| More on:
Hands grabbing for high rung on a ladder pointing to the sky

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Investors are responding positively to an update from Resapp today
  • The company was awarded a patent in China
  • UBS says the Chinese telehealth market is expected to reach US$54 billion by 2025
  • In the last year, the Resapp share price has climbed 20% into the green

Shares in digital health company Resapp Health Ltd (ASX: RAP) are walking higher today following a company announcement.

At the time of writing the Resapp share price has spiked 5% from the open and is now fetching 7.9 cents apiece after rallying as high as 13% in early trading.

Investors are responding positively to an update regarding a cough analysis patent that was awarded in China, piling into the company on a volume of 193% of its 4-week average volume.

Resapp has cough analysis patent granted in China

Resapp touts itself as a "leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease".

The company integrates machine learning algorithms that use sound to diagnose and measure the severity of respiratory conditions.

It has two flagship products in the field, called ResAppDx – a smartphone app for respiratory diagnostics and telehealth; and SleepCheck, another app that assesses sleep apnoea.

As such, the company had applied for a patent in China under the title "A method and apparatus for processing patient sounds", according to the release.

Today the company advised that the China National Intellectual Property Administration has accepted for grant the company's patent application.

The patent covers the use of a "cough sound-based audio processing pipeline for diagnosing respiratory disease", Resapp says, and is owned by The University of Queensland. It will be licensed exclusively to ResApp for the lifetime of the patent.

Resapp says this "pivotal patent family" has also been granted in Australia, Japan, Korea and the US, and is currently pending approval in Europe.

Management commentary

Speaking on the announcement, Resapp CEO and Managing Director, Dr Tony Keating said:

Receiving this patent grant for our core technology is a key step in our market entry plans for China. China presents multiple large market opportunities for ResApp's products. According to UBS, the Chinese telehealth market is expected to reach US$54B by 2025, and there is a critical need for triage tools in China's overburdened hospitals. China also has over 45 million people with asthma and 100 million people with COPD, which brings large opportunities in chronic disease management. Our team has discussions underway regarding pathways to enter the Chinese market and realise the value of these opportunities.

Resapp share price snapshot

The chart below shows Resapp's underperformance relative to the S&P/ASX 200 Index (ASX: XJO) and the S&P/ASX Small Ordinaries Index (ASX: XSO) over the last 12 months.

Note the wide-reaching volatility Resapp shareholders have had to endure in this time, meaning that the stock's risk-adjusted performance might be called into question.

Even still, with a breakout of 21% since January 1, shares are now back in line with the broad market once more. In the last year, the Resapp share price has climbed 20% into the green.

TradingView Chart

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »